Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + rituximab in relapsed or refractory primary central nervous system lymphoma
2012-003786-17Phase 2Completed
- Sponsor
- Institut Curie
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide and rituximab in primary central nervous system lymphoma (PCNSL) and intraocular lymphoma, sponsored by Institut Curie. Primary endpoint: Objective response rate at end of induction. Started Apr 2013; status: completed.
02
Drugs
lenalidomiderituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)intraocular lymphoma
Beyond the preview
Go deeper on 2012-003786-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003786-17.